Bristol Myers Squibb announced results from the Phase 3 CheckMate -651 trial comparing Opdivo (nivolumab) plus Yervoy (ipilimumab) to the EXTREME regimen (cetuximab, cisplatin/carboplatin and fluorouracil) as a first-line…
Seres Therapeutics announced topline results from the Phase 2b ECO-RESET study evaluating SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The study did not meet…
Polyphor provided an update on its global Phase III study, FORTRESS, evaluating balixafortide (POL6326) in combination with eribulin versus eribulin alone for the treatment of…
A leading European oncology professional association reports that adding an immune checkpoint inhibitor known as Atezolizumab (Tecentriq) to anti-HER2 treatment in breast cancer fails to…
Vertex Pharmaceuticals reported results from a phase 2 study evaluating the efficacy and safety of VX-864 in patients with alpha-1 antitrypsin deficiency (AATD) with the…
AB Sciences announced that it has taken the decision to suspend inclusions and treatment initiation in its clinical studies with masitinib worldwide. This decision follows…
Sanofi announced it is halting the pivotal phase 2/3 STAGED-PKD study, evaluating venglustat versus placebo in patients at risk of rapidly progressive Autosomal Dominant Polycystic Kidney Disease. The…
Novartis reported one year results of the Phase 3 MERLIN study, assessing the efficacy and safety of Beovu (brolucizumab-dbll) 6 mg versus Eylea (aflibercept) 2 mg…
British pharmaceutical company AstraZeneca reports that data resulting from a late-stage clinical trial investigating whether its diabetes drug called Farxiga can treat patients hospitalized with…
Another National Institute of Allergy and Infectious Diseases (NIAID)-backed large scale COVID-19 experiment failed to meet endpoints as the CoVIg-19 Plasma Alliance recently shared that…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
